The short answer: Most people regain a large share of the weight after stopping Mounjaro (tirzepatide), but usually not all of it within the first year. In the SURMOUNT-4 trial, people who switched to placebo after 36 weeks of tirzepatide regained 14.0% of their body weight over the next 52 weeks. They still finished 9.9% below their starting weight, while people who stayed on the drug finished 25.3% below it. The regain looks like the pattern seen after stopping semaglutide, and it happens because appetite hormones and energy use shift back toward the pre-treatment state.
What happened when people stopped Mounjaro in SURMOUNT-4?
SURMOUNT-4 is the main trial on this question. It was published in JAMA in January 2024 by Aronne and colleagues. The study enrolled 783 adults with obesity or overweight and no diabetes. Everyone took open-label tirzepatide for 36 weeks. Doses were pushed to the maximum tolerated: 92.7% reached 15 mg and 7.3% stopped at 10 mg. Mean weight loss during that lead-in was 20.9%.
At week 36, 670 people were randomized. Half continued tirzepatide and half switched to placebo, blinded. Everyone kept getting lifestyle counseling for another 52 weeks, to week 88.
- Continued tirzepatide: lost a further 5.5% from week 36 to week 88. Total loss from baseline was 25.3%.
- Switched to placebo: regained 14.0% of body weight from week 36 to week 88. Total loss from baseline was 9.9%.
- Kept at least 80% of the lead-in loss: 89.5% on tirzepatide versus 16.6% on placebo.
Eli Lilly funded the trial, and the counseling was more structured than routine care. For the on-treatment results across the SURMOUNT program, see our Mounjaro weight loss results page.
How much of the weight loss was kept after one year off?
Measured against the starting weight, the placebo group kept about half of what they lost. They were 20.9% down at week 36 and 9.9% down at week 88. A 2026 post hoc analysis in JAMA Internal Medicine looked at the 308 placebo-switch participants who had lost at least 10% during the lead-in. It sorted them by how much of their lost weight came back by week 88:
- Less than 25% regained: 54 people (17.5%).
- 25% to under 50% regained: 77 people.
- 50% to under 75% regained: 103 people.
- 75% or more regained: 74 people.
So 82.5% regained at least a quarter of their loss. The most common outcome was regaining half to three-quarters. Health markers tracked the weight. Waist circumference rose 0.8 cm in the lowest regain group and 14.7 cm in the highest. Systolic blood pressure rose 6.8 mm Hg versus 10.4 mm Hg. HbA1c rose 0.14% versus 0.35%.
A real-world follow-up of the SURMOUNT-CN trial points the same way. It tracked 152 people for 26 weeks after treatment ended. Those who had taken 15 mg regained 12.3% of body weight in six months and sat 10.6% below baseline. Only 53.1% of them still held a 10% loss.
How does this compare with stopping semaglutide?
Semaglutide has a near-identical study. The STEP 1 extension, published by Wilding and colleagues in Diabetes, Obesity and Metabolism in 2022, followed 327 people for one year after 68 weeks of semaglutide 2.4 mg or placebo, with lifestyle support withdrawn too. The semaglutide group had lost 17.3%. Off treatment, they regained 11.6 percentage points and finished 5.6% below baseline. The authors called it two-thirds of the loss regained. Blood pressure returned to baseline. Lipids and C-reactive protein stayed somewhat better than placebo.
The two trials are not a head-to-head test. STEP 1 dropped both the drug and the counseling, while SURMOUNT-4 kept the counseling. Still, a 2026 meta-regression in eClinicalMedicine that pooled six randomized trials and 3,236 participants found the regain curves "broadly similar" across liraglutide, semaglutide, and tirzepatide. Its model put regain at 60% of lost weight one year after stopping, with a half-life of 23.0 weeks and a plateau near 75.3% of the loss. Our sister site covers the semaglutide side in Ozempic weight regain.
Why does the weight come back?
Tirzepatide does not reset the body's weight regulation. It overrides it while the drug is present. Three things happen when it leaves.
Appetite returns. The Mounjaro label says tirzepatide activates GIP and GLP-1 receptors and "decreases food intake." Its half-life is about five days, so most of the drug is gone within a few weeks. The effect on food intake goes with it.
Hunger hormones favor regain after any weight loss. In a 2011 NEJM study, 50 adults lost a mean of 13.5 kg on a very-low-energy diet. One year later, leptin and peptide YY were still low, ghrelin was still high, and hunger ratings were still raised. The authors called these "circulating mediators of appetite that encourage weight regain." Tirzepatide quiets that signal. Stopping exposes it.
Energy use falls. A smaller body burns fewer calories, and the drop often exceeds what body size predicts. In the six-year Biggest Loser follow-up, resting metabolic rate was 704 kcal per day below baseline. Of that, 499 kcal per day was beyond what the new body size explained. That study used extreme diet and exercise, not a drug, but it shows how persistent the adaptation can be.
The NIDDK states this plainly: "You probably will regain some weight after you stop taking weight management medication."
Who regains less?
Trials have not found a reliable predictor. The JAMA Internal Medicine analysis reported "no apparent differences in baseline demographic and clinical characteristics" between people who regained under 25% and those who regained 75% or more.
The SURMOUNT-CN follow-up did find two signals. Larger weight loss during treatment and early regain by week 56 both predicted more regain. Self-reported adherence to lifestyle consultations predicted less. The eClinicalMedicine review also noted a study where a carbohydrate-restricted diet after stopping led to "negligible weight regain." These are small, observational findings. They support structured follow-up after the last dose, but they are not a guarantee.
Does tapering or a lower maintenance dose help?
The evidence is thin. The Mounjaro label gives escalation steps of 2.5 mg after at least four weeks on each dose, up to 15 mg. It says nothing about how to come off the drug. There is no FDA-labeled taper. See our dosing schedule page for what the label does cover.
The eClinicalMedicine review found one report in which mean weight did not rise after people reduced their semaglutide dose under a tapering protocol. That is a single study, not a trial. The direct test for tirzepatide is SURMOUNT-MAINTAIN (NCT06047548). After a 60-week weight-loss phase, it randomizes about 320 people to continue their maximum tolerated dose, drop to 5 mg, or switch to placebo for 52 weeks. Completion was expected in May 2026, and results were not published when this article was written. Until then, a low maintenance dose is plausible but unproven.
How can you limit regain after stopping?
No strategy has been shown to fully prevent regain in a randomized trial. These steps have the best support for limiting it.
- Plan the stop with your prescriber. Set a follow-up schedule for the first year. That is when the regain curve is steepest.
- Keep protein high. Preserving muscle protects resting energy use. Our muscle loss article lays out the 1.2 to 1.6 g per kg range from published reviews.
- Lift weights two to three times a week. Resistance training kept lean mass stable in meta-analyses of dieting adults.
- Keep the lifestyle program going. Adherence to counseling was the one modifiable factor tied to less regain in the SURMOUNT-CN follow-up.
- Treat obesity as chronic. The NIDDK says a prescriber may recommend staying on a drug indefinitely if it works and is tolerated. Restarting is an option if weight returns.
The bottom line
Yes, most people regain weight after stopping Mounjaro. In SURMOUNT-4, the placebo group regained 14.0% of body weight in one year and kept roughly half its original loss. About four in five regained at least a quarter of what they had lost. The pattern matches semaglutide, where two-thirds of the loss returned within a year. Returning appetite, persistent hunger hormones, and lower energy use drive the regain, not lack of effort. No taper is on the label, and the maintenance-dose trial has not reported. Protein, resistance training, and structured follow-up are the tools with evidence today.
Last updated: September 2026. This article is for informational purposes only and does not constitute medical advice. Talk with your prescriber before stopping, pausing, or changing your Mounjaro dose.